High-Level Overview
IOMED is a Barcelona-based health tech company founded in 2016 that builds an AI-powered Data Space Platform to activate and standardize healthcare data from structured and unstructured sources, including electronic health records (EHR) and human-written notes.[1][2][3][5] It serves healthcare organizations (data holders like hospitals), research organizations, and contract research organizations (data users) by solving the problem of unlocking raw, siloed clinical data for secondary use—such as research, clinical trials, and data-driven decision-making—while ensuring compliance, data privacy via federated models (data never leaves hospital systems), and standardization to the OMOP Common Data Model.[1][3][4] With $6 million in 2025 revenue, 41-57 employees, over 21 million patients' data activated, 50+ strategic partners, 13+ active hospitals, and 40+ research projects, IOMED demonstrates strong growth momentum, including international expansion and certifications like ISO 27001, EHDEN, and OHDSI partnership.[1][3]
Origin Story
IOMED's idea emerged in 2015 when co-founder Gabriel Maeztu, during his research, identified inefficiencies in data collection and patient recruitment from unstructured healthcare records.[5] In 2016, Maeztu, along with co-founders Álvaro Abella and Javier de Oca, launched the company in Castelldefels, Catalonia (near Barcelona), developing AI and Natural Language Processing (NLP) technology to bridge this gap.[1][5][6] Early deployment in Barcelona hospitals led to nationwide expansion in Spain by 2020, marked by a €2 million funding round led by Adara Ventures (with EASO Ventures and Speedinvest) to grow into Germany and the UK; pivotal moments include exponential traction, peer-reviewed publications, and evolution into a global Data Space Mediator.[5][6] Today, Gabriel Maeztu serves as Co-Founder, President, and CTO.[1]
Core Differentiators
- AI-Powered Data Activation and NLP: Extracts and understands complex clinical data (e.g., temporal nuances, negation) from structured/unstructured sources like EHR, automating terminology mapping to OMOP CDM for interoperability.[2][3][4]
- Federated Data Model and Privacy: Data stays on-site in hospitals, enabling secure sharing across a network of 13+ hospitals and 175+ primary care sites without compromising GDPR compliance or ISO 27001 standards.[1][3][4]
- Data Quality and Validation: Dual assurance with expert physician annotators, statistical tests, and clinical validation for high-reliability real-world data (RWD), supporting 21M+ patients and 30+ years of data.[3][4]
- Data Space Enablement and Mediation: For data holders, enables 360° patient views; for users, facilitates compliant secondary use via federated network, OHDSI tools, and multilingual adaptation, accelerating research and trials.[3][4]
- Ecosystem and Certifications: EHDEN-certified SME, OHDSI partner, EU Seal of Excellence, Top 50 CB Insights, with 40+ research projects and peer-reviewed publications.[3]
Role in the Broader Tech Landscape
IOMED rides the wave of the European Health Data Space (EHDS) and global push for real-world evidence (RWE) in healthcare, where fragmented, unstructured data (90% of records) hinders AI-driven research, personalized medicine, and clinical trials.[3][4][5] Timing is ideal amid EU regulations mandating data interoperability (e.g., OMOP/OHDSI standards) and post-pandemic demand for federated learning to balance privacy with collaboration, positioning IOMED as a key mediator in a market projected to grow with health data spaces.[3][4] Favorable forces include rising RWD needs for drug development, hospital digitalization, and AI adoption; IOMED influences the ecosystem by powering 450K+ impacted patients, 45+ research projects, and cross-border networks, fostering a data-driven healthcare shift while upholding ethical standards.[3]
Quick Take & Future Outlook
IOMED is poised for accelerated European and global scaling as EHDS rolls out, leveraging its federated network and AI edge to capture demand from pharma, CROs, and hospitals seeking compliant RWE.[3][5] Trends like multimodal AI, predictive analytics, and multinational data commons will amplify its role, potentially driving revenue beyond $6M through new partnerships and U.S./Asia entry. Its influence may evolve from enabler to standard-setter in health data spaces, transforming siloed records into evidence-based care—IOMED isn't just activating data; it's powering the future of precision healthcare.[1][3][5]
